Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen (NASDAQ: AKAO), Castlight Health (NYSE: CSLT), and Ironwood Pharmaceuticals (NASDAQ: IRWD), in addition to serving on the Board of several other private companies. Past investments include athenahealth (NASDAQ: ATHN), CodeRyte (acquired by 3M), Ikaria (acquired by Madison Dearborn), Illumina (NASDAQ: ILMN) and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking healthcare investor on Forbes’ Midas List since 2008.
Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.